Molecular Formula: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight: ~4731–4845 g/mol
CAS Number: 2381089‑83‑2
COA (certificate of analysis) provided: Retatrutide Purity Report 99.8_ HPLC
Purity: 99.8% HPLC

Product Video:

Peptide Calculator

Retatrutide is an investigational medication developed by Eli Lilly. It’s a triple agonist that acts on three key metabolic receptors:

Retatrutide – “weight loss king” (brief, straight to the point):

What it is

• A next-gen triple-action weight loss injection (GLP-1 + GIP + glucagon agonist)
• Developed by Eli Lilly, currently in Phase 3 trials (not yet approved)

Why it’s called the “king”

• Hits 3 fat-loss pathways at once → appetite, blood sugar, AND metabolism
• Early trials show ~24–28% body weight loss (very high vs other drugs)
• Some patients lost 70+ lbs on average in trials

GLP‑1 (glucagon-like peptide‑1)
GIP (glucose-dependent insulinotropic polypeptide)
Glucagon receptor

By activating all three, retatrutide aims to improve blood sugar control and promote weight loss more effectively than current single or dual agonist drugs (like semaglutide or tirzepatide).
Key Points:

Mechanism: It enhances insulin secretion, reduces appetite, slows gastric emptying, and increases energy expenditure.
Use: Primarily being studied for obesity, type 2 diabetes, and related cardiometabolic diseases.
Clinical Results: In early and mid-stage clinical trials, participants saw substantial weight reductions (often over 20%) over several months—greater than with currently approved GLP‑1 agonists.
Status: As of 2024, retatrutide is still in clinical trials and has not yet been approved for general medical use.

Why It’s Getting Attention

Very large weight‑loss effects: early trials show up to ~25% body‑weight reduction in under a year, nearly double the effect of Ozempic‑class drugs.

Dual mechanism: reduces appetite and increases metabolic rate, accelerating fat loss.

Safety & Concerns

Potential side effects include nausea, gastrointestinal symptoms, and more serious concerns such as bone fractures and kidney issues reported in some trial participants.

Rapid weight loss risks: some participants lost weight so quickly they skipped doses to slow the effect.

Reconstitute with BAC’s Water.
When reconstituting peptides, it is crucial to use bacteriostatic water (BAC) to ensure sterility and safety.
BAC water contains 0.9% Benzyl Alcohol and is bacteria-proof, making it the preferred choice for reconstitution.
This method helps preserve the integrity of the peptide and prevents contamination.

To reconstitute a peptide blend, follow these steps:
Disinfect both vials and the stoppers with alcohol wipes.
Measure the required amount of BAC water based on the dosage.
Mix the peptide powder with the measured BAC water in a sterile syringe.
Inject the solution into the vial and refrigerate at 2–8°C, protected from light.
Use the reconstituted solution within 4 weeks for best potency and safety.
Always consult with a Professional healthcare provider before embarking on a new research project involving reconstituting peptides

Legal and Safety Information;
Quantum Peptides products are provided exclusively for laboratory research and educational use.
They are not approved for human or veterinary applications.
These materials are not intended to diagnose, treat, cure, or prevent any medical condition.
All use must adhere to applicable laws and regulatory requirements.

“The photo is for illustration purposes only and includes as much product information as possible. Bottle labels wrap around the container and may vary slightly in design & between batches as part of our anti‑counterfeiting measures.”